AU2005303778B2 - S-mirtazapine for the treatment of hot flush - Google Patents

S-mirtazapine for the treatment of hot flush Download PDF

Info

Publication number
AU2005303778B2
AU2005303778B2 AU2005303778A AU2005303778A AU2005303778B2 AU 2005303778 B2 AU2005303778 B2 AU 2005303778B2 AU 2005303778 A AU2005303778 A AU 2005303778A AU 2005303778 A AU2005303778 A AU 2005303778A AU 2005303778 B2 AU2005303778 B2 AU 2005303778B2
Authority
AU
Australia
Prior art keywords
treatment
mirtazapine
week
rats
vasomotor symptoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
AU2005303778A
Other languages
English (en)
Other versions
AU2005303778A1 (en
Inventor
Anton Egbert Peter Adang
B.W.M.M. Bernardus Peeters
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Organon NV
Original Assignee
Organon NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34929859&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AU2005303778(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Organon NV filed Critical Organon NV
Publication of AU2005303778A1 publication Critical patent/AU2005303778A1/en
Application granted granted Critical
Publication of AU2005303778B2 publication Critical patent/AU2005303778B2/en
Assigned to MSD OSS B.V. reassignment MSD OSS B.V. Request to Amend Deed and Register Assignors: N.V. ORGANON
Assigned to MERCK SHARP & DOHME B.V. reassignment MERCK SHARP & DOHME B.V. Request to Amend Deed and Register Assignors: MSD OSS B.V.
Assigned to N.V. ORGANON reassignment N.V. ORGANON Request for Assignment Assignors: MERCK SHARP & DOHME B.V.
Anticipated expiration legal-status Critical
Expired legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
AU2005303778A 2004-11-15 2005-11-14 S-mirtazapine for the treatment of hot flush Expired AU2005303778B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP04105778.7 2004-11-15
EP04105778 2004-11-15
PCT/EP2005/055947 WO2006051111A1 (en) 2004-11-15 2005-11-14 S-mirtazapine for the treatment of hot flush

Publications (2)

Publication Number Publication Date
AU2005303778A1 AU2005303778A1 (en) 2006-05-18
AU2005303778B2 true AU2005303778B2 (en) 2011-02-17

Family

ID=34929859

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005303778A Expired AU2005303778B2 (en) 2004-11-15 2005-11-14 S-mirtazapine for the treatment of hot flush

Country Status (30)

Country Link
US (4) US20070265245A1 (enExample)
EP (1) EP1814555B1 (enExample)
JP (1) JP2008519810A (enExample)
KR (1) KR20070085470A (enExample)
CN (2) CN101056641A (enExample)
AR (1) AR053780A1 (enExample)
AT (1) ATE439843T1 (enExample)
AU (1) AU2005303778B2 (enExample)
BR (1) BRPI0517818A2 (enExample)
CA (1) CA2587283C (enExample)
CY (1) CY1110538T1 (enExample)
DE (1) DE602005016141D1 (enExample)
DK (1) DK1814555T3 (enExample)
ES (1) ES2329815T3 (enExample)
HR (1) HRP20090513T1 (enExample)
IL (1) IL182767A (enExample)
MX (1) MX2007005827A (enExample)
MY (1) MY144089A (enExample)
NO (1) NO20072285L (enExample)
NZ (1) NZ554858A (enExample)
PE (1) PE20061051A1 (enExample)
PL (1) PL1814555T3 (enExample)
PT (1) PT1814555E (enExample)
RS (1) RS51138B (enExample)
RU (1) RU2396957C2 (enExample)
SI (1) SI1814555T1 (enExample)
TW (1) TW200631584A (enExample)
UA (1) UA88655C2 (enExample)
WO (1) WO2006051111A1 (enExample)
ZA (1) ZA200703884B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007002174A2 (en) * 2005-06-27 2007-01-04 N.V. Organon. A method of treatment of hormone depletion induced vasomotor symptoms
US20070129611A1 (en) * 2005-12-06 2007-06-07 University Of North Texas Health Science Center At Fort Worth System, Method and Apparatus for Assessing Menopausal or Post-Hysterectomy Symptoms
EP1993556A1 (en) * 2006-03-06 2008-11-26 N.V. Organon An improved method of weaning from hormonal treatment of hormone depletion induced vasomotor symptoms
AU2007324467A1 (en) * 2006-11-22 2008-05-29 N.V. Organon Vaginal delivery system for mirtazapine
US7645750B2 (en) * 2006-12-13 2010-01-12 Yung Shin Pharmaceutical Ind. Co., Ltd. Method of treating symptoms of hormonal variations
JP2009018992A (ja) 2007-07-10 2009-01-29 Sumitomo Chemical Co Ltd 光学活性ミルタザピンの製造方法
US8420624B2 (en) 2007-12-04 2013-04-16 Yung Shin Pharm. Ind. Co., Ltd. Methods for treating or preventing symptoms of hormonal variations
JP6876003B2 (ja) 2015-02-27 2021-05-26 デクラ リミテッド イヌ及びネコにおける、食欲の刺激、体重減少の管理、及び拒食症の処置
KR102608479B1 (ko) * 2017-05-25 2023-12-01 글리테크 엘엘씨. Nmdar 길항제-반응성 신경정신 질환을 위한 병용 요법
WO2021167579A1 (ru) 2020-02-19 2021-08-26 Иван УЛИНИЧ Универсальное устройство для тепловой обработки пищевых продуктов

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL189199C (nl) * 1975-04-05 1993-02-01 Akzo Nv Werkwijze ter bereiding van farmaceutische preparaten met werking op het centraal zenuwstelsel op basis van benz(aryl)azepinederivaten, de verkregen gevormde farmaceutische preparaten, alsmede werkwijze ter bereiding van de toe te passen benz(aryl)azepinederivaten.
US4515792A (en) * 1982-09-30 1985-05-07 Ciba-Geigy Corporation Tetracyclic heterocycles and antidepressant compositions thereof
JPH1187727A (ja) * 1997-09-12 1999-03-30 Mitsubishi Electric Corp 半導体装置
ES2212550T3 (es) * 1998-04-02 2004-07-16 Akzo Nobel N.V. Solucion oral liquida que comprende el antidepresor mirtazapina.
RU2195951C1 (ru) * 2001-08-20 2003-01-10 Общество с ограниченной ответственностью "Лаборатория "Ирис" Средство для лечения климактерических расстройств

Also Published As

Publication number Publication date
AR053780A1 (es) 2007-05-23
CN102772414A (zh) 2012-11-14
MX2007005827A (es) 2007-07-20
ES2329815T3 (es) 2009-12-01
CA2587283A1 (en) 2006-05-18
EP1814555B1 (en) 2009-08-19
CA2587283C (en) 2013-01-15
US20100267694A1 (en) 2010-10-21
HRP20090513T1 (hr) 2009-10-31
US20070265245A1 (en) 2007-11-15
PT1814555E (pt) 2009-09-30
NZ554858A (en) 2009-10-30
ATE439843T1 (de) 2009-09-15
PL1814555T3 (pl) 2010-01-29
IL182767A (en) 2011-07-31
KR20070085470A (ko) 2007-08-27
PE20061051A1 (es) 2006-10-26
MY144089A (en) 2011-08-15
CY1110538T1 (el) 2015-04-29
IL182767A0 (en) 2007-09-20
UA88655C2 (ru) 2009-11-10
NO20072285L (no) 2007-06-13
CN101056641A (zh) 2007-10-17
RU2396957C2 (ru) 2010-08-20
RS51138B (sr) 2010-10-31
US20120302552A1 (en) 2012-11-29
HK1104235A1 (en) 2008-01-11
US20130225559A1 (en) 2013-08-29
DE602005016141D1 (de) 2009-10-01
AU2005303778A1 (en) 2006-05-18
EP1814555A1 (en) 2007-08-08
RU2007122391A (ru) 2008-12-20
JP2008519810A (ja) 2008-06-12
DK1814555T3 (da) 2009-12-07
SI1814555T1 (sl) 2009-12-31
WO2006051111A1 (en) 2006-05-18
ZA200703884B (en) 2009-07-29
TW200631584A (en) 2006-09-16
BRPI0517818A2 (pt) 2010-03-16

Similar Documents

Publication Publication Date Title
US20120302552A1 (en) S-mirtazapine for the treatment of hot flush
TWI330083B (en) Methods for treating or preventing symptoms of hormonal variations
JP3194734B2 (ja) 迅速作用性選択的セロトニン再摂取阻害剤を用いた性的不全の処置方法
EA002554B1 (ru) Применение кабэрголина при лечении синдрома усталых ног
PL185528B1 (pl) Kompozycja farmaceutyczna do modulowania przepływu krwi do genitaliów i zastosowanie fentolaminy do wytwarzania leku do leczenia impotencji
JP6137833B2 (ja) 脱髄性および他の神経系疾患を患っている患者における神経認知的および／または神経精神医学的障害を改善するための４−アミノピリジンの使用
WO2025128594A1 (en) Methods of treating generalized anxiety disorder
KR100367792B1 (ko) 테트라하이드로벤즈[cd]인돌-6-카복스아미드를 포함하는 성기능부전 치료용 약제
MX2010012179A (es) Composicion farmaceutica para el tratamiento de eyaculacion prematura.
RU2768875C2 (ru) Композиции для лечения и профилактики вазомоторных симптомов
CA2443019C (en) Kappa-opiate agonists for the treatment of bladder diseases
AU2020206399A1 (en) Use of chlorogenic acid in preparing medicine or pharmaceutical composition for preventing or treating pain
EP3060214A2 (en) Cns stimulant and opioid receptor antagonist combination as a non- addictive, non-aversive and synergistic anti-obesity treatment
AU2008240374A1 (en) Sustained release
HK1104235B (en) S-mirtazapine for the treatment of hot flush
CN109310691A (zh) 用于快速开始抗抑郁作用的给药方案
WO2007125295A2 (en) Treatment of hypothyroidism
RU2761219C2 (ru) Терапевтическое средство от расстройств, связанных с употреблением алкоголя
JP2002542198A (ja) 抗躁薬および気分変動の安定薬としてのルビジウムおよび特に塩化ルビジウムの使用
TABLETS MAXALT®

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: N.V. ORGANON

Free format text: FORMER OWNER(S): MERCK SHARP & DOHME B.V.

MK14 Patent ceased section 143(a) (annual fees not paid) or expired